Loading viewer...
investor_presentation
Format: PDF investor_presentation
Investor Conference Call: Q3 2019 Earnings and XPOVIO®Launch Update November 4, 2019
Investor Conference Call:
Q3 2019 Earnings and XPOVIO®Launch Update
November 4, 2019 2 ©2019 Karyopharm Therapeutics Inc. •Michael G. Kauffman, MD, PhD, Chief Executive Officer
•Perry Monaco, Senior Vice President, Sales
•Mike Mason, MBA, Chief Financial OfficerOn Today’s Call
•Sharon Shacham, PhD, MBA , President and Chief Scientific Officer
•Christopher Primiano, JD, MBA , Chief Business Officer, General Counsel
•Ian Karp, MBA, Vice President, Investor and Public RelationsJoining for
Q&A Session 3 ©2019 Karyopharm Therapeutics Inc. This presentation contains forward- looking statements within themeaning ofthe“safe harbor” provisions ofThe Private Securities Litigation Reform Actof1995 .Such forward-
looking statements include those regarding Karyopharm’s expectations relating toXPOVIO®forthetreatment ofpatients with heavily pretreated multiple myeloma, thetherapeutic
potential ofandpotential clinical development plans andcommercialization forKaryopharm’s drug candidates, including thetiming ofinitiation ofcertain trials, ofthereporting of
data from such trials, ofthesubmissions toregulatory authorities andofpotential commercial launches, thepotential availability ofaccelerated approval pathways, thepotential size
ofthemarkets formultiple myeloma drugs andmultiple myeloma drugs fortreatment ofpatients withrelapsed multiple myeloma andKaryopharm’s strategic andfinancial plans and
expectations aswellasfinancial projections forKaryopharm .Such statements aresubject tonumerous important factors, risks anduncertainties thatmay cause actual events or
results todiffer materially from Karyopharm’s current expectations .Forexample, there canbenoguarantee that Karyopharm willsuccessfully commercialize XPOVIO, that
regulators willagree that selinexor qualifies forconditional approval intheE.U.asaresult ofthedata from theSTORM study inpatients with penta -refractory myeloma or
accelerated approval intheU.S.based ontheSADAL study inpatients with relapsed/refractory DLBCL orthatanyofKaryopharm’s drug candidates, including selinexor and
eltanexor (KPT -8602 ),Karyopharm’s second generation SINE compound, orKPT-9274, Karyopharm’s first-in-class oraldual inhibitor ofPAK4 and NAMPT, oranyother drug
candidate Karyopharm isdeveloping, willsuccessfully complete necessary preclinical andclinical development phases orthatdevelopment ofanyofKaryopharm’s drug candidates
willcontinue. Further, there canbenoguarantee thatanypositive developments inKaryopharm’s drug candidate portfolio willresult instock price appreciation. Inaddition, even if
Karyopharm receives marketing approval forselinexor inadditional indications orforanyother drug candidate, there canbenoassurance that Karyopharm willbeable to
successfully commercialize thatdrug candidate .Management’s expectations and, therefore, anyforward- looking statements inthispresentation could also beaffected byrisks and
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
32 Pages
Ainsworth Game Technology
Precision Drilling January 2024 Investor Presentation
investor_presentationinvestor_presentation
28 Pages
Precision Drilling Corporation